Special Report

As blood-based biomarkers continue to reshape the diagnostic landscape of Alzheimer's disease, clinicians are gaining new tools to identify underlying pathology earlier, improve diagnostic confidence, and better select patients for emerging disease-modifying therapies. Presented at the 2026 Alzheimer's Association International Conference (AAIC), the analysis "Blood Biomarker Assays Demonstrate Strong Rule-In Performance for Identifying Cognitively Unimpaired Alzheimer's Disease" adds to a growing body of evidence supporting plasma P-tau217 as a scalable and clinically meaningful approach for detecting amyloid pathology before dementia develops.

In this NeurologyLive^® Special Report, Yogesh Shah, MD, MPH, FAAFP, medical director of the Broadlawns Memory Clinic, site principal investigator for the University of Iowa Geriatric Workforce Empowerment Program, and board member of the Iowa Chapter of the Alzheimer's Association, examines the biology underlying Alzheimer's disease, reviews the performance of P-tau217 blood-based assays presented at AAIC 2026, and discusses what these findings could mean for diagnosis, patient selection, and the future of Alzheimer's care as blood-based testing moves closer to routine clinical practice.

Thymidine kinase 2 deficiency is an ultra-rare, life-threatening mitochondrial myopathy that, until recently, had no approved treatment options beyond supportive care. The FDA approval of doxecitine and doxribtimine in November 2025 -- followed by EMA approval in March 2026 -- marked a turning point for patients, particularly those with early symptom onset. In this Special Report, Dr. Michio Hirano, a lead author of the pivotal publication in Brain Communications and a central figure in TK2d research, breaks down the integrated efficacy and safety data, what it means for clinical practice, and where the field goes from here.

In this video program, Mitzi Joi Williams, MD, discussed the role of ofatumumab, a high-efficacy anti-CD20 therapy, in relapsing multiple sclerosis (MS). She described the shift toward using high-efficacy agents earlier, key clinical and patient factors that guide selection, and the practical impact of at-home, subcutaneous administration. She also reviewed long-term efficacy data and NEDA-based goals, outlined safety and infection monitoring, emphasized shared decision-making and concerns about self-injection, and noted future questions around treatment sequencing, progressive MS, older adults, trial diversity, and global access.

This Special Report will explore emerging insights from the phase 3 INDIGO trial evaluating vorasidenib in IDH-mutant diffuse glioma, with a focus on its impact on seizure burden and underlying tumor biology. Through discussion of exploratory analyses, the conversation will examine the relationship between tumor volume reduction, 2-HG suppression, and seizure control, while highlighting the clinical importance of earlier intervention following gross total resection and its potential implications for patient quality of life and long-term disease management.

This NeurologyLive® Special Report explores phase 3, placebo-controlled data on fenfluramine in patients with CDKL5 deficiency disorder (CDD), presented at the 2026 American Academy of Neurology Annual Meeting. Featuring insights from Sam Amin, MD, the discussion focuses on seizure reduction, global clinical outcomes, and safety observations in this ultra-rare, treatment-resistant epilepsy. The series aims to contextualize these findings within the broader landscape of developmental and epileptic encephalopathies and highlight considerations for clinical care and future research.

This Special Report will provide a comprehensive clinical overview of the 52-week data from the phase 3 MINT trial evaluating inebilizumab in AChR-positive generalized myasthenia gravis. The discussion will explore the biologic rationale for CD19-targeted B-cell depletion, key efficacy and safety outcomes through one year, and pharmacodynamic and immunogenicity findings, while contextualizing how these data may inform evolving treatment strategies and future research in gMG.

This Special Report will explore emerging insights from the phase 3 INDIGO trial evaluating vorasidenib in IDH-mutant diffuse glioma, with a focus on its impact on seizure burden and underlying tumor biology. Through discussion of exploratory analyses, the conversation will examine the relationship between tumor volume reduction, 2-HG suppression, and seizure control, while highlighting the clinical importance of earlier intervention following gross total resection and its potential implications for patient quality of life and long-term disease management.

In this NeurologyLive® Special Report, Bruce Cree, MD, PhD, Clinical Research Director at the UCSF Multiple Sclerosis Center, discusses recently published 5-year data from the ULTIMATE trials and open-label extension of Ublituximab. The conversation reviews key efficacy outcomes, including relapse rates, disability progression, and functional measures, along with longer-term safety observations. Dr. Cree also provides clinical context on how these findings fit within the broader landscape of anti-CD20 therapies for relapsing multiple sclerosis. The series aims to support clinicians in interpreting long-term data and its relevance to treatment decision-making.

In this 5-part panel discussion series, Shamik Bhattacharyya, MD, Anne M. Finucane Endowed Chair in Neurology and Associate Professor of Neurology at Harvard Medical School, and Philippe-Antoine Bilodeau, MD, of the Division of Neuroimmunology at Mass General Brigham and Instructor in Neurology at Harvard Medical School, unpack their recent real-world comparative effectiveness study published in Neurology. Drawing on decades of institutional data, the panel examines how FDA-approved NMOSD therapies perform relative to rituximab and traditional immunosuppressants, while addressing key methodological and safety considerations that shape clinical practice.

Independent content by Neurology Live with support from Catalyst Pharmaceuticals Medical Affairs.

In this NeurologyLive^® Special Report mini-series, Scott Perry, MD, Co-Director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital, discusses zorevunersen, an investigational antisense oligonucleotide therapy in development for Dravet syndrome. Across five focused episodes, Dr. Perry explains the science behind zorevunersen’s gene-targeting mechanism, reviews early-phase clinical findings, and highlights its potential to modify disease course beyond seizure control. He also provides insight into the ongoing phase 3 EMPEROR trial and shares perspectives on how disease-modifying strategies may transform the treatment landscape. The series offers neurologists an in-depth look at a novel approach aiming to address the root cause of Dravet syndrome.

In this NeurologyLive® Special Report mini-series, Riley Bove, MD, Associate Professor of Neurology at the University of California, San Francisco, provides expert insights on ofatumumab and its evolving role in multiple sclerosis care. Dr. Bove discusses how the therapy compares with other DMTs, reviews pivotal data from the ARTIOS trial, and reflects on its growing clinical applications since FDA approval. She also addresses emerging considerations around patient subgroups, long-term safety, and real-world utilization of this self-administered B-cell–depleting treatment. Across four focused episodes, neurologists gain valuable takeaways on where ofatumumab fits into current and future MS treatment strategies.

This conference coverage information is produced independently by Neurology Live and Supported by Eli Lilly and Company who has no direct influence on the content itself.

Alzheimer disease experts provide commentary on findings from the TRAILBLAZER-ALZ 6 study at the 2025 Alzheimer’s Association International Conference.

In this special report series from NeurologyLive, sleep specialists Eric Olson, MD, and Anita Shelgikar, MD, president-elect of the AASM, offer expert commentary on six late-breaking presentations from the 2025 SLEEP Annual Meeting in Seattle. The panel examines key findings in narcolepsy and hypersomnia, including new data on the cardiovascular safety and high-dose efficacy of low-sodium oxybate, real-world prescribing trends, and the role of social determinants of health in clinical outcomes. The discussion also explores investigational therapies such as TAK-861 and ALKS 2680, highlighting their mechanisms, study designs, and potential clinical implications. Together, these insights provide a timely update on the evolving treatment landscape for central disorders of hypersomnolence.

Movement disorders expert Fernando L Pagan, MD, provides commentary on several presentations of innovative therapies for Parkinson disease from the 2025 American Academy of Neurology Annual Meeting.

Movement disorders expert Fernando L Pagan, MD, shares insights on emerging therapeutics for Parkinson disease, reflects on the evolution of the neurology field, and offers practical guidance for clinicians.

Aravindhan Veerapandiyan, MD, discusses how del-zota (delpacibart zotadirsen), an exon 44 skipping agent using antibody-conjugated phosphorodiamidate morpholino oligomer (PMO) technology, demonstrated favorable safety, significant dystrophin production (25% of normal), and unprecedented reduction of creatine kinase levels to near-normal in patients with Duchenne muscular dystrophy (DMD) during phase 1/2 clinical trials.

Movement disorder and Parkinson disease specialist Stuart Isaacson, MD, discussed SPN-830 after the subcutaneous apomorphine infusion device's FDA approval.

Multiple sclerosis experts Patricia Coyle, MD, FAAN, and Adnan Subei, DO, FAAN, cover the long-term impacts of S1P-modulating treatments for MS, the differences in each treatment, and how the class has evolved since the first therapeutic over 10 years ago.

Movement disorder experts Robert Hauser, MD, MBA, and Hubert Fernandez, MD, discuss the recently approved IPX203 (Crexont; Amneal Pharmaceuticals) for the treatment of patients with Parkinson disease.

Multiple Sclerosis expert Donald Negroski, MD, provides clinical insight on a number of abstracts from the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting focused on treatment changes and care for aging patients with MS.

Parkinson disease expert Daniel Kremens, MD, JD, offers commentary on various presentations of novel therapies from the 2024 American Academy of Neurology Annual Meeting.

Highlights from the 2023 World Stroke Congress are provided through medical expert perspectives.

Multiple sclerosis experts discuss long-term safety and efficacy data on S1P receptors modulators and other updates from EAN 2023.

An expert neurologist discusses the use of neurofilament light chain (NfL) as a biomarker in multiple sclerosis (MS), highlighting clinical trials and updates from a recent conference.

Stuart H. Isaacson, MD, FAAN, an expert in the care of patients with Parkinson disease, discusses data on novel treatments for Parkinson disease and how these therapies can affect the care paradigm.

Stuart H. Isaacson, MD, FAAN, an expert in the care of patients with Parkinson disease, shares in-depth perspectives on personalizing management plans and data from the 2023 AAN Annual Meeting.

Experts in the management of multiple sclerosis discuss the latest understanding of how disease progression and treatment affect cognition.

Multiple sclerosis experts discuss data from four presentations on ozanimod, a disease modifying therapy that was presented at EAN 2022.

Key opinion leaders and presenters offer their insight on the latest advances in the management of patients with multiple sclerosis at the 2022 Consortium of Multiple Sclerosis Centers annual meeting.